Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?

Author(s): Andrea Bortolato, Giorgio Cozza, Stefano Moro

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 8 , Issue 7 , 2008

Become EABM
Become Reviewer
Call for Editor


Protein kinase CK2 is a ubiquitous, essential, and highly pleiotropic protein kinase whose abnormally high constitutive activity is suspected to underlie its pathogenic potential in neoplasia and other diseases. A number of structurally unrelated CK2 inhibitors, tested on a variety of cells derived from tumours, including lymphomas, leukaemias, multiple myeloma and prostate carcinoma, display a proapoptotic effect which is roughly proportional to their in vitro inhibitory potency. In the present review we summarize the most recent discovery of potent and selective CK2 inhibitors and their prospective as future anticancer agents.

Keywords: Protein kinase CK2, casein kinase 2, anticancer drugs, drug discovery

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [798 - 806]
Pages: 9
DOI: 10.2174/187152008785914761
Price: $65

Article Metrics

PDF: 5